- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07620080
EYEMAX® Versus SPYGLASS™ DS for Biliary Stricture Diagnosis (EYE/SPY)
Multicenter Study on the Quality of Biliary Biopsies: EYEMAX® vs SPYGLASS™ DS
Cholangiocarcinoma remains difficult to diagnose because of the limited sensitivity of currently available endobiliary sampling techniques. Cholangioscopy-guided biopsies performed with the SPYGLASS™ DS system have improved tissue acquisition compared with conventional brushing techniques, but diagnostic sensitivity remains suboptimal, partly because of the small diameter of the dedicated biopsy forceps.
The EYEMAX® cholangioscopy system has a larger working channel, potentially allowing the use of larger biopsy forceps and improved tissue acquisition. This multicenter randomized study aims to compare the diagnostic performance of EYEMAX® versus SPYGLASS™ DS for the diagnosis of malignant biliary strictures.
The primary objective is to compare the positive diagnostic yield of the first four cholangioscopy-guided biopsies obtained with each system in patients with adenocarcinomatous biliary strictures.
연구 개요
연구 유형
등록 (추정된)
단계
- 해당 없음
연락처 및 위치
연구 연락처
- 이름: David KARSENTI, MD
- 전화번호: +33 1 43 96 78 50
- 이메일: karsenti.paris@gmail.com
연구 연락처 백업
- 이름: MORENO MAIRA, PhD
- 이메일: rechercheclinique@sfed.org
참여기준
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
설명
Inclusion Criteria:
- 1. Adult patients aged 18 to 84 years
- 2. Patients requiring ERCP with cholangioscopy-guided biopsy for biliary stricture
- 3. Absence of a mass easily accessible to EUS-guided fine needle aspiration
- 4. ASA physical status 1-3
- 5. No participation in another clinical trial
- 6. Written informed consent obtained
- 7. Patient affiliated with a social security system or equivalent
Exclusion Criteria:
- 1. Lithiasic biliary obstruction
- 2. Patients younger than 18 years
- 3. ASA 4 or ASA 5 patients
- 4. Pregnant or breastfeeding women
- 5. Coagulation disorders preventing biopsy procedures
- 6. Surgical anatomy preventing papillary access
- 7. Patients unable to provide informed consent
- 8. Upper gastrointestinal obstruction
- 9. Intolerance to endoscopy
- 10. Severe cardiopulmonary disease
- 11. Acute pancreatitis or severe cholangitis
- 12. Severe contrast agent allergy
- 13. Patients under legal protection measures
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 특수 증상
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Cholangioscopy-guided biliary biopsies performed using the EYEMAX® cholangioscope (Micro-Tech).
|
Cholangioscopy-guided biliary biopsies performed using the EYEMAX® cholangioscope (Micro-Tech) during ERCP under general anesthesia.
Following biliary cannulation and guidewire passage across the stricture, two series of four targeted biopsies are obtained using the dedicated biopsy forceps through the EYEMAX® working channel.
Additional diagnostic sampling procedures, including biliary brushing, fluoroscopy-guided biopsies, bile aspiration cytology, and EUS-guided sampling when clinically indicated, may also be performed according to local practice.
|
|
활성 비교기: Cholangioscopy-guided biliary biopsies performed using the SPYGLASS™ DS system (Boston Scientific).
|
Cholangioscopy-guided biliary biopsies performed using the SPYGLASS™ DS cholangioscopy system (Boston Scientific) during ERCP under general anesthesia.
Following biliary cannulation and guidewire passage across the stricture, two series of four targeted biopsies are obtained using the dedicated biopsy forceps through the SPYGLASS™ DS working channel.
Additional diagnostic sampling procedures, including biliary brushing, fluoroscopy-guided biopsies, bile aspiration cytology, and EUS-guided sampling when clinically indicated, may also be performed according to local practice.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Percentage of positive pathological diagnoses obtained from the first four cholangioscopy-guided biopsies
기간: Through study completion, an average of 1 year
|
The positive diagnostic yield will be assessed for the first four biopsies obtained under cholangioscopy in patients with adenocarcinomatous biliary strictures.
This rate will be defined as the ratio between the number of positive pathological diagnoses obtained from the first four cholangioscopy-guided biopsies and the total number of confirmed adenocarcinomatous biliary strictures.
|
Through study completion, an average of 1 year
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Positive diagnostic yield of all eight cholangioscopy-guided biopsies
기간: Through study completion, an average of 1 year
|
This rate will be defined as the proportion of positive pathological diagnoses obtained from all eight cholangioscopy-guided biopsies among all confirmed adenocarcinomatous biliary strictures.
|
Through study completion, an average of 1 year
|
|
Histological cellularity classification of cholangioscopy-guided biopsy specimens
기간: Through study completion, an average of 1 year
|
Biopsy specimen cellularity will be assessed by expert gastrointestinal pathologists and classified into four predefined categories: acellular, low abundance, satisfactory abundance, or rich abundance.
|
Through study completion, an average of 1 year
|
|
False negative rate of cholangioscopy-guided biopsies
기간: Through study completion, an average of 1 year
|
The false negative rate will be defined as the proportion of patients with negative biopsy results despite a final diagnosis of adenocarcinomatous biliary stricture confirmed during follow-up.
|
Through study completion, an average of 1 year
|
|
Negative predictive value of cholangioscopy-guided biopsies
기간: Through study completion, an average of 1 year
|
Negative predictive value will be calculated as the proportion of patients with negative biopsy results who do not have adenocarcinomatous biliary strictures at final diagnosis.
|
Through study completion, an average of 1 year
|
|
Percentage of technical failures during cholangioscopy-guided biopsy procedures
기간: Periprocedural
|
Technical failure will be defined as the inability to access the biliary stricture with the cholangioscope or the inability to obtain biopsy material using the dedicated biopsy forceps.
|
Periprocedural
|
|
Diagnostic yield of additional biliary sampling techniques
기간: Through study completion, an average of 1 year
|
The diagnostic yield of additional biliary sampling techniques, including biliary brushing, fluoroscopy-guided biopsies, bile aspiration cytology, and EUS-guided sampling, will be evaluated as the proportion of positive pathological diagnoses obtained using each technique.
|
Through study completion, an average of 1 year
|
|
Number of participants with procedure-related adverse events
기간: Up to Day 30
|
Procedure-related adverse events include abdominal pain, acute pancreatitis, cholangitis, cholecystitis, hepatic abscess, perforation, bleeding, and death.
|
Up to Day 30
|
|
Mean duration of cholangioscopy-guided biopsy procedures
기간: Periprocedural
|
The duration required to complete the eight cholangioscopy-guided biopsies will be measured and compared between the two cholangioscopy systems.
|
Periprocedural
|
공동 작업자 및 조사자
스폰서
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- SFED-160
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .